News
Article
ICYMI: Highlights From ACCC Spring 2023
Author(s):
Our most-read coverage from the Association of Community Cancer Centers (ACCC) 2023 Annual Meeting and Cancer Center Business Summit highlighted ongoing issues in oncology policy and practice.
Our most-read coverage from the Association of Community Cancer Centers (ACCC) 2023 Annual Meeting and Cancer Center Business Summit highlighted ongoing issues in oncology policy and practice.
Here are the ACCC 2023 conference highlights. Click here to catch up on all of our coverage from the conference.
5. Stops and Starts Abound in the Oncology Payment Landscape
In a presentation at the Association of Community Cancer Centers (ACCC) 2023 Annual Meeting and Cancer Center Business Summit, government affairs experts took attendees through updates and considerations around several policies. The halt of the Cures 2.0 bill, legal challenges to the No Surprises Act, and ongoing issues with the 340B drug pricing program were discussed by government affairs experts during the session.
4. Dr Kevin Davies: There Is Great Potential for CRISPR in Genetic Diseases and Cancers
Technology has come a long way since the initial discovery of the DNA double helix. ACCC keynote speaker Kevin Davies, PhD, executive editor of The CRISPR Journal and GEN Biotechnology, and author of Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing, discussed the promise of CRISPR genome editing an interview with The American Journal of Managed Care®.
3. Multicancer Early Detection May Change the Screening Game—If We Learn From the Past
Multicancer early detection (MCED) technology has the potential to increase the number of cancers that can be found early on, but the potential of MCED testing can only be realized with consideration for the possible risks associated with new technology in this space. Like any novel technology, there are pros and cons to its implementation and lessons to learn along the way. Presenters agreed that gradual and intentional introduction of technology such as MCED testing is crucial.
2. CRISPR Holds Promise in Cancer Treatment, but Challenges Remain
In a keynote presentation that also served as a celebration of the 70th anniversary of the discovery of the DNA double helix—an essential first step to modern-day genomic sequencing and gene editing technology—Kevin Davies, PhD, brought attendees along on a journey through history centered on the development of CRISPR genome editing technology, as well as its potential in cancer therapy.
1. Even Oncologists Sold on Value-Based Care Hesitate to Embrace the EOM
On paper, the goals of value-based reimbursement models tend to align with the goals of most oncologists, but developing a model that works for all oncology stakeholders has proven difficult. In this discussion ahead of the Enhancing Oncology Model (EOM), which launched in July, members of the ACCC Alternative Payment Coalition and representatives from the CMS Center for Medicare and Medicaid Innovation talked through findings from the Oncology Care Model and concerns surrounding the EOM.
